Drug
Navlimetostat clinical trials
Also written BMS-986504 and MRTX1719.
Keep track of what changes. Save the navlimetostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
13 studies that test it; most in 2026 (8)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2025 | 4 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 5
Bristol-Myers Squibb (8) · University of Southampton (1) · M.D. Anderson Cancer Center (1) · Northwestern University (1) · Ankit Mangla, MD (1) · Nader Sanai (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses navlimetostat is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingPhase 2/3Bristol-Myers SquibbNCT07063745Written as BMS-986504
- A Phase 1 Study of Navlimetostat Tablet FormulationsRecruitingPhase 1Bristol-Myers SquibbNCT07544628Written as Navlimetostat
- A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy ParticipantsRecruitingPhase 1Bristol-Myers SquibbNCT07800897Written as Navlimetostat
- Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung CancerRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07579221Written as Navlimetostat
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionRecruitingPhase 1Bristol-Myers SquibbNCT05245500Written as MRTX1719
- BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP DeletionRecruitingPhase 1/2Northwestern UniversityNCT07594626Written as PRMT5 Inhibitor BMS-986504
- A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female ParticipantsNot yet recruitingPhase 1Bristol-Myers SquibbNCT07777133Written as Navlimetostat
- Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath TumorRecruitingPhase 1/2Ankit Mangla, MDNCT07549022Written as BMS-986504
- Clinical Trial of BMS-986504 in Recurrent GBM PatientsRecruitingEarly Phase 1Nader SanaiNCT06883747Written as BMS-986504
- A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase DeletionRecruitingPhase 1Bristol-Myers SquibbNCT06672523Written as BMS-986504
- A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid TumorsRecruitingPhase 1Bristol-Myers SquibbNCT07077434Written as BMS-986504
- SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed MesotheliomaNot yet recruitingPhase 2University of SouthamptonNCT07602946Written as BMS-986504
- A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)Active, not recruitingPhase 2/3Bristol-Myers SquibbNCT07076121Written as Navlimetostat
Given in every arm · 5 — navlimetostat is usual care beside what is tested
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingPhase 2Bristol-Myers SquibbNCT07492680Written as BMS-986504
- A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT07283705Written as BMS-986504
- A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)RecruitingPhase 2Bristol-Myers SquibbNCT06855771Written as BMS-986504
- A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07532902Written as BMS-986504
- Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP LossRecruitingPhase 1M.D. Anderson Cancer CenterNCT07382544Written as MRTX1719
Codes
What other systems call navlimetostat · ClinicalTrials.gg INT018133
- UNII (FDA) UHN5PKM648NAVLIMETOSTATOne source FDA
- NCI Thesaurus C215286NavlimetostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UHN5PKM648 | NAVLIMETOSTAT | One source FDA |
| NCI Thesaurus | C215286 | Navlimetostat | One source FDA |
Also registered as mrtx-1719, (s)- (UNII AY4A8WD6JS).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.